PRPH vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 02, 2026

PRPH

40.1
AI Score
VS
PRPH Wins

CDNA

25.6
AI Score

Investment Advisor Scores

PRPH

40score
Recommendation
HOLD

CDNA

26score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PRPH CDNA Winner
Revenue 2.18M 249.65M CDNA
Net Income -8.23M 113.44M CDNA
Net Margin -377.3% 45.4% CDNA
Operating Income -5.07M 114.42M CDNA
ROE 264.4% 26.7% PRPH
ROA -14.3% 21.3% CDNA
Total Assets 57.41M 532.99M CDNA
Cash 20,000 373.64M CDNA
Current Ratio 0.05 4.58 CDNA

Relative Price Performance (Last 90 Days)

PRPH 1M: +157.2% · 3M: -29.6% CDNA 1M: +13.5% · 3M: +128.7%

Current Technical Phase

PRPH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.4 · Price: $0.36

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.1% over 20 days), RSI 65

RSI (14): 65.5 · Price: $50.88

Fundamentals Snapshot

Metric PRPH CDNA
Market Cap
Forward P/E 10.1 38.3
Trailing P/E 24.0
Revenue (TTM)
Revenue Growth -0.4% 0.5%
Gross Margin 0.2% 0.7%
Operating Margin -5.4% 0.0%
EPS -19.80 2.08
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PRPH is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.